Retatrutide

Retatrutide – Injectable (5 mg × 10 Vials / 10 mg × 10 Vials / 12 mg × 10 Vials / 15 mg × 10 Vials / 20 mg × 10 Vials / 24 mg × 10 Vials / 30 mg × 10 Vials / 36 mg × 10 Vials / 40 mg × 10 Vials / 50 mg × 10 Vials / 60 mg × 10 Vials)

Retatrutide is a potent next-generation triple-agonist peptide engineered to activate GLP-1, GIP, and glucagon receptors simultaneously. This multi-pathway design delivers powerful appetite suppression, improved glucose regulation, and increased energy expenditure, making it one of the strongest metabolic research peptides available. Its extended-activity structure produces significantly greater weight-loss potential than single-agonist or dual-agonist peptides.

Available Formats:

5 mg × 10 sterile vials
10 mg × 10 sterile vials
12 mg × 10 sterile vials
15 mg × 10 sterile vials
20 mg × 10 sterile vials
24 mg × 10 sterile vials
30 mg × 10 sterile vials
36 mg × 10 sterile vials
40 mg × 10 sterile vials
50 mg × 10 sterile vials
60 mg × 10 sterile vials

Chemical Composition:

Type: GLP-1 / GIP / Glucagon triple-agonist peptide
Structure: Long-chain modified incretin-based polypeptide
Molecular Weight: ~4.8 kDa

Administration (Injectable):

Supplied as a lyophilized peptide intended for subcutaneous injection after reconstitution with bacteriostatic water. Research protocols typically use weekly administration due to the prolonged receptor activation profile, with dosing dependent on concentration and study requirements.

Benefits & Key Features:

Triple-pathway receptor activation for superior metabolic impact
Strong appetite suppression and reduced caloric intake
Supports improved glucose control and insulin sensitivity
Increases metabolic rate and energy expenditure
Highly stable lyophilized formula in sealed sterile vials

Product Notes:

For research and laboratory use only.
Must be reconstituted before administration.
Sterile, injectable-grade peptide.